This is a working overview of Mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-02. Anything still debated is marked as such rather than presented as settled.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Growth of spermatogenic tissue in testicles, male fertility, penis or clitoris enlargement, increased libido and frequency of erection or clitoral engorgement occurs. Growth of jaw, brow, chin, and nose and remodeling of facial bone contours, in conjunction with human growth hormone occurs. Completion of bone maturation and termination of growth. This occurs indirectly via estradiol metabolites and hence more gradually in men than women. Increased muscle strength and mass, shoulders become broader and rib cage expands, deepening of voice, growth of the Adam's apple. Enlargement of sebaceous glands. This enlargement might cause acne, subcutaneous fat in face decreases. Pubic hair extends to thighs and up toward umbilicus, development of facial hair (sideburns, beard, moustache), loss of scalp hair (androgenetic alopecia), increase in chest hair, periareolar hair, perianal hair, leg hair, armpit hair.
=== Weight loss === Bupropion, when used for treating long-term weight gain over six to twelve months, results in an average weight loss of 2.7 kilograms (6.0 lb) compared to a placebo. This is not much different from the weight loss produced by several other weight-loss medications, such as sibutramine and orlistat. The combination drug naltrexone/bupropion has been approved by the US Food and Drug Administration (FDA) for the treatment of obesity.
Cooperatives also play a great part in banking. Cooperative banks in India serve both the rural and urban societies. Just like the sugar companies, these institutions serve as the power base for local politicians.
=== 3D graphene === In 2013, a three-dimensional honeycomb of hexagonally arranged carbon was termed 3D graphene, and self-supporting 3D graphene was also produced. 3D structures of graphene can be fabricated by using either CVD or solution-based methods. A 2016 review by Khurram and Xu et al. provided a summary of then-state-of-the-art techniques for fabrication of the 3D structure of graphene and other related two-dimensional materials. In 2013, researchers at Stony Brook University reported a novel radical-initiated crosslinking method to fabricate porous 3D free-standing architectures of graphene and carbon nanotubes using nanomaterials as building blocks without any polymer matrix as support. These 3D graphenes (all-carbon) scaffolds/foams have applications in several fields such as energy storage, filtration, thermal management, and biomedical devices and implants. Box-shaped graphene (BSG) nanostructure appearing after mechanical cleavage of pyrolytic graphite was reported in 2016. The discovered nanostructure is a multilayer system of parallel hollow nanochannels located along the surface and having quadrangular cross-section. The thickness of the channel walls is approximately equal to 1 nm.
=== Normal === In healthy adults, the normal concentrations of CRP varies between 0.8 mg/L and 3.0 mg/L. However, some healthy adults show elevated CRP at 10 mg/L. CRP concentrations also increase with age, possibly due to subclinical conditions. Additionally, there are seasonal variations of CRP concentrations, with highest levels occurring in the winter. Gene polymorphism of interleukin-1 family, interleukin 6, and polymorphic GT repeat of the CRP gene do affect the usual CRP concentrations when a person does not have any medical illnesses.
Sources: en.wikipedia.org
== Australian and New Zealand Society for Mass Spectrometry == The major awards from the Australian and New Zealand Society for Mass Spectrometry (ANZSMS) are the ANZSMS Medal, Morrison Medal, Bowel Medal, Michael Guilhaus Research Award and ANZSMS Fellows.
Commission B1: Thermodynamics and Transfer Processes The objectives of Commission B1 on Thermodynamics and Transfer Processes are to provide academic and industrial information and data, and to propose any solutions on thermodynamics and transfer processes. The Commission B1 has been extremely active in IIR Working Groups, sub-commissions, IIR conferences, co-sponsored conferences, and commission business meetings. As well as being involved in IIR Working Groups on the mitigation of direct emissions of greenhouse gases in refrigeration, the commission is equally involved in the Working Group on Life Cycle Climate Performance (LCCP) Evaluation. Active in IIR conferences and congresses, Commission B1 similarly organises workshops in various fields such as refrigerant charge reduction in refrigerating systems. Initiatives and opportunities, such as the phase-down of high-GWP refrigerants, energy-efficient buildings and cars, transport refrigeration, food preservation, the economic importance of the refrigeration sector, the involvement of the younger generation and identifying industrial needs are all at the heart of Commission B1.
==== Invasion of Iraq ==== Planning for the Operation Iraqi Freedom began in December 2001; in 2002 several teams of 10th SFG and CIA SAD operatives were infiltrated into Iraqi Kurdistan in advance of hostilities. They were based in the Harir valley outside Irbil and tasked to develop ground truth intelligence while organising and training the Peshmerga; they were also there to monitor Ansar al-Islam and plan for a future operation against them. For the 2003 invasion of Iraq, CJSOTF-West (Combined Joint Special Operations Task Force-West/Task Force Dagger) was formed around the 5th SFG, their ODAs were tasked with two core missions: the first – to counter the SCUD TELs and by denying the Iraqi military the use of potential launch sites and the second – provide both intelligence-gathering and screening function in support of conventional forces to build up an accurate picture of Iraqi force dispositions in western Iraq. The Green Beret ODAs were deployed under the command and control of ODBs (Operational Detachment Bravo) which operated as roving AOBs (Advanced Operating Bases), these AOBs provided a mobile resupply function using their modified M1078 Light Medium Transport Vehicles which meant that the ODA patrols could operate for extended periods in enemy territory before linking up with a fighting patrol that would be escorting the AOBs for combat resupply.
==== NIH Toolbox ==== In September 2006, the NIH Blueprint for Neuroscience Research started a contract for the NIH Toolbox for the Assessment of Neurological and Behavioral Function to develop a set of state-of-the-art measurement tools to enhance collection of data in large cohort studies. More than 250 scientists from almost 100 academic institutions contributed to its development. In September 2012, the NIH Toolbox was rolled out to the research community. NIH Toolbox assessments are based, where possible, on Item Response Theory and adapted for testing by computer.
Sources: en.wikipedia.org
==== Alpidem ==== Alpidem is a nonbenzodiazepine anxiolytic with similar anxiolytic effectiveness as benzodiazepines but reduced sedation and cognitive, memory, and motor impairment. It was marketed briefly in France but was withdrawn from the market due to liver toxicity.
== History == Canakinumab was being developed by Novartis for the treatment of rheumatoid arthritis, but this trial was completed in October 2009. Canakinumab is also in phase I clinical trials as a possible treatment for chronic obstructive pulmonary disease, gout, and coronary artery disease (the CANTOS trial). It is also in trials for schizophrenia. In gout, it may result in better outcomes than a low dose of a steroid, but costs five thousand times more. The U.S. Food and Drug Administration (FDA) approved canakinumab for CAPS in June 2009, followed by the European Medicines Agency (EMA) in October. In August 2017, the results of the CANTOS trial were announced at the European Society of Cardiology. Those treated in CANTOS had a 15% reduction in deaths from heart attacks, stroke and cardiovascular disease combined. However, CANTOS reported serious side-effects and no statistically significant overall survival benefit.
Kato K, Kawahara K, Takahashi T, Kakinuma A (1980). "Purification of an α-amino acid ester hydrolase from Xanthomonas citri". Agric. Biol. Chem. 44: 1069–1074. doi:10.1271/bbb1961.44.1069. Kato K, Kawahara K, Takahashi T, Kakinuma A (1980). "Substrate specificity of an α-amino acid ester hydrolase from Xanthomonas citri". Agric. Biol. Chem. 44: 1075–1081. doi:10.1271/bbb1961.44.1075. Takahashi T, Yamazaki Y, Kato K (1974). "Substrate specificity of an α-amino acid ester hydrolase produced by Acetobacter turbidans A.T.C.C. 9325". Biochem. J. 137 (3): 497–503. doi:10.1042/bj1370497. PMC 1166149. PMID 4424889.
== Further reading == Brady JE, Humiston GE & Heikkinen H (1980), "Chemistry of the Representative Elements: Part II, The Metalloids and Nonmetals", in General Chemistry: Principles and Structure, 2nd ed., SI version, John Wiley & Sons, New York, pp. 537–91, ISBN 0-471-06315-0 Chedd G (1969), Half-way Elements: The Technology of Metalloids, Doubleday, New York Choppin GR & Johnsen RH (1972), "Group IV and the Metalloids", in Introductory Chemistry, Addison-Wesley, Reading, Massachusetts, pp. 341–57 Dunstan S (1968), "The Metalloids", in Principles of Chemistry, D. Van Nostrand Company, London, pp. 407–39 Goldsmith RH (1982), "Metalloids", Journal of Chemical Education, vol. 59, no. 6, pp. 526527, doi:10.1021/ed059p526 Hawkes SJ (2001), "Semimetallicity", Journal of Chemical Education, vol. 78, no. 12, pp. 1686–87, doi:10.1021/ed078p1686 Metcalfe HC, Williams JE & Castka JF (1974), "Aluminum and the Metalloids", in Modern Chemistry, Holt, Rinehart and Winston, New York, pp. 538–57, ISBN 0-03-089450-6 Miller JS (2019), "Viewpoint: Metalloids – An Electronic Band Structure Perspective", Chemistry – A European Perspective, preprint version, doi:10.1002/chem.201903167 Moeller T, Bailar JC, Kleinberg J, Guss CO, Castellion ME & Metz C (1989), "Carbon and the Semiconducting Elements", in Chemistry, with Inorganic Qualitative Analysis, 3rd ed., Harcourt Brace Jovanovich, San Diego, pp. 742–75, ISBN 0-15-506492-4 Parveen N et al.
=== Popular culture === Abuse and addiction to cortisone was the subject of the 1956 motion picture Bigger Than Life, produced by and starring James Mason. Though it was a box-office flop upon its initial release, many modern critics hail the film as a masterpiece and brilliant indictment of contemporary attitudes toward mental illness and addiction. In 1963, Jean-Luc Godard named it one of the ten greatest American sound films ever made. John F. Kennedy was regularly administered corticosteroids such as cortisone as a treatment for Addison's disease.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.